Purpose: To assess the effects of postmenopausal hormone replacement therapy (HRT) on intraocular pressure (IOP).
INTRODUCTION
Glaucoma is a leading cause of irreversible blindness throughout the world. World Health Organization statistics, published in 1995, indicate that glaucoma accounts for blindness in 5.1 million people, or 13.5% of global blindness. 1 In the United States, it is the second leading cause of blindness and the most frequent cause among African Americans. Glaucoma is also the second most common reason for ambulatory visits to ophthalmologists in the US by Medicare beneficiaries. 2 Glaucomatous optic neuropathy is defined as progressive loss of visual field, most commonly associated with increased intraocular pressure (IOP), with characteristic optic disc and nerve fiber layer damage. 3 Previous data indicate possible correlation between IOP and hormonal variations in women. [4] [5] [6] [7] Thus far, only a few studies have investigated the effect of postmenopausal hormone replacement therapy (HRT) on IOP. These studies reported a decrease in IOP within 2 to 3 months from the initiation of therapy. [8] [9] [10] However, a recent study failed to find any correlation between postmenopausal HRT and IOP. 11 The current study aimed to assess the effect of postmenopausal HRT and lifetime estrogen and progesterone exposure on IOP.
MATERIALS AND METHODS
This was a prospective cross-sectional controlled study. We offered all patients aged 60 to 80 years, who were visiting the Hadassah Medical Center's Women's Health Clinic between June 1999 and January 2002 and who were receiving HRT for at least 12 consecutive months to enroll in the study. Additionally, we offered all women of the same age group visiting this clinic for routine evaluation who have never received HRT to serve as controls. All participants signed an informed consent approved by the Institutional Review Board Committee for Human Subjects. All completed a standardized questionnaire, which included data on age, body mass index, personal and family history of glaucoma, cardiovascular and cerebrovascular disease, vascular risk factors (including smoking history, hyperlipidemia, and hypertension), and lifetime estrogen and progesterone exposure, including type and duration of HRT, previous use of oral contraceptives, gravidity, parity, age at menarche, and age at menopause.
All subjects were tested for visual acuity, with and without eyeglasses, using a standard Snellen chart. In addition, each participant underwent bilateral IOP assessment 3 times consecutively by 1 of 3 expert ophthalmologists (EB, CY, and GA) using a Perkins applanation tonometer. The average of these 3 measurements was taken as the final value. All examiners were blinded to whether the subjects were receiving HRT or not. The intraobserver reliability for IOP measurements was good with a weighted kappa of 0.81 (95% confidence interval 0.73-0.88).
Horizontal and vertical cup-to-disc (C/D) ratios were measured bilaterally using slit-lamp biomicroscopy and a 90-diopter lens. Each patient underwent bilateral stereoscopic fundus photography centered on the optic disk. Photographs were separately read by each ophthalmologist for horizontal and vertical C/D ratios using a fluorescent viewing box and a 35 magnification stereoscopic viewer. All discordant results (11 patients from the HRT group and 9 patients from the non-HRT group) were adjudicated openly. This resulted in resolution of all discordances. The interobserver reliability for C/D ratios was good with a weighted kappa of 0.71 (95% confidence interval 0.63-0.74).
Comparisons between HRT and non-HRT groups were analyzed using independent Student's t test for continuous variables and x 2 test for categorical variables. We used a multivariate logistic regression model, with increased IOP as the dependent variable, to screen each risk factor separately for an association with increased IOP. In addition, we used a multiple linear regression model to screen for possible confounding factors for differences in IOPs between the HRT and the non-HRT groups, including age, family history of glaucoma, myopic refraction, child births, menstruation years, years of HRT, years of OC use, personal and family history of cardiovascular and cerebrovascular disease, smoking history, hypercholesterolemia, hypertriglyceridemia, hypertension, and body mass index. SPSS package for Microsoft Windows (version 11.0) was used for all statistical analyses with P values ,0.05 being considered statistically significant. Power analysis calculations and sample size estimation were based on studies reporting a 13% decrease in IOP following hormone replacement therapy in postmenopausal women. [8] [9] [10] With 80% power and 5% significance, Za and Zb were calculated to be 1.94 and 0.81, respectively. Based on these calculations we estimated our sample size to be 98 patients in each group.
RESULTS
One hundred forty-nine consecutive eligible women receiving HRT were offered to participate in this study, of which 107 (72%) agreed to enroll. Of these 107 women, ninety-five (89%) were receiving combined estrogen and progesterone, and 12 (11%) were receiving estrogen only preparations. One hundred fifty-three consecutive eligible women who have never received HRT were offered to participate in this study and 107 (70%) consented to enroll.
No significant differences were noted between the HRT and the non-HRT groups with regard to age, cerebrovascular disease, personal and family history of cardiovascular disease, body mass index, and vascular risk factors, including hyperlipidemia, hypertension, and smoking habits (Table 1) . No significant differences were noted between the two groups in lifetime estrogen and progesterone exposure, including oral contraceptive use, pregnancies, live births, and menstruation years (Table 1) . Ophthalmic characteristics, including personal and family history of glaucoma, visual acuity, IOP, prevalence of increased IOP, and C/D ratios were not significantly different between the two groups ( Table 2) . Eight patients (7%) of each group had abnormal C/D ratios, defined as .0.5 in either horizontal or vertical dimensions. None of the patients had C/D ratios of .0.7. These results remained unchanged Values are represented as means 6 SD. Numbers in brackets represent percentages. HRT, hormone replacement therapy. *As measured in the eye with the highest value (most affected eye); †Defined as .21 mm Hg; ‡Defined as .0.5 in either horizontal or vertical dimension.
following stratification into estrogen and progesterone versus estrogen only therapies (data not shown).
Thirty-one (15%) of 214 patients who enrolled in this study were found to have increased IOP (defined as .21 mm Hg) in at least one eye. Personal history of ischemic heart disease was the only risk factor that was significantly associated with elevated IOP (O.R. = 4.63, P = 0.003) ( Table 3 ). This finding remained valid after adjustment for possible confounding factors such as age and vascular risk factors. Age, body mass index, family history of glaucoma, and vascular risk factors were not significantly associated with increased IOP. No association was found between number of pregnancies, live births, menstruation years, previous use of oral contraceptives or HRT, and the risk for increased IOP (Table 4) .
DISCUSSION
The results presented herein suggest that IOP may not be affected by postmenopausal HRT, or lifetime estrogen and progesterone exposure. Glaucoma is currently considered the leading cause of irreversible blindness in the world. It is defined as progressive optic neuropathy with characteristic optic disc and nerve fiber layer damage, usually associated with loss of visual function. 12 The IOP is the most important risk factor for the disease, although a small proportion of patients do not have elevated IOP. A number of epidemiologic factors have come to be associated with elevated IOP, including age, sex, blood pressure, juvenile diabetes mellitus, inheritance, obesity, pulse rate, stature, and myopia. 13 An increasing body of data indicates that HRT exerts beneficial vasodilatory and anti-atherosclerotic effects in several vascular beds.
14 Women, more than men, lose cerebral vasoreactivity with age. 15 Estrogen replacement therapy blunts this loss of responsivity and mitigates age-linked changes in arterial structure and distensibility. 16 It increases low-density lipoprotein catabolism as well as lipoprotein receptor activity, resulting in decreased low-density lipoprotein and elevated high-density lipoprotein serum concentrations. 17, 18 It also inhibits the development of atherosclerotic lesions by means of one or more mechanisms independently of any effects on lipids and lipoproteins. 19 Nevertheless, the Women's Health Initiative has reported a detrimental effect for this treatment on cardiovascular and cerebrovascular disease. 20 These inconsistent data concerning the vascular effects of postmenopausal HRT have raised the question of whether this treatment may affect IOP. Glaucoma is associated with evidence of increased vascular resistance within the ophthalmic, central retinal, and short posterior ciliary arterial watersheds. 21 In addition, there seems to be a link between systemic cardiovascular disease, 14, 22, 23 vascular risk factors, 24, 25 and glaucoma. The current study detected an increased risk for ocular hypertension in patients with a personal history of ischemic heart disease.
Intraocular pressure is the result of a complex interplay of the components of aqueous humor dynamics, especially the rate of aqueous production, the resistance to aqueous outflow, and the episcleral venous pressure. 3 The logical target tissues for hormonal effect on IOP are the ciliary epithelia and the subepithelial vascular plexus, the trabecular meshwork and outflow channels, and the episcleral venous plexus. Hormones may act upon the inflow of aqueous humor, thereby affecting IOP either by altering the pressure gradient available for ultrafiltration, or by modifying the forces within the ciliary epithelia that govern the secretion of ions and water. The trabecular meshwork and outflow channels are also susceptible to regulation by hormonal factors. There is evidence that corticotropin, vasopressin, thyroxin, insulin, glucocorticoids, and mineralocorticoids may play a role in the physiologic regulation of IOP. 7 Several studies have investigated the effect of estrogen and progesterone on IOP. Ofri et al 26 reported increased IOP during ovulation in female cats. They also found that elevated progesterone levels associated with the luteal phase in lionesses caused increased resistance to aqueous humor outflow, Values are represented as means 6 SD. Numbers in brackets represent percentages. IOP, intraocular pressure; OR, multivariate-adjusted odds ratios; CI, confidence interval. *Statistically significant difference; †not including patients with previous history of glaucoma. The multivariate analysis included the following variables: age, family history of glaucoma, myopic refraction, child births, menstruation years, years of HRT, years of OC use, personal and family history of cardiovascular and cerebrovascular disease, smoking history, hypercholesterolemia, hypertriglyceridemia, hypertension, and body mass index.
q 2005 Lippincott Williams & Wilkins leading to IOP elevation. 27 In humans however, no clear-cut correlation between IOP and serum estrogen or progesterone levels during the menstrual cycle could be demonstrated. [28] [29] [30] [31] [32] Decreased IOP has been reported during the entire course of pregnancy and after delivery. 6, 33 Increased outflow facility has been measured in pregnant women. 34 Some studies reported an increase in pulsatile ocular blood flow throughout gestation, which they related to estrogen or progesterone-induced vasodilatation. 6, 35 Only a few studies have addressed the question of whether oral contraceptives may affect IOP. 36 Our study did not detect any effect of lifetime estrogen and progesterone exposure (including years of menstruation, number of pregnancies, and the use of oral contraceptives) on IOP; however, it was not primarily designed or powered to address this question.
Although the effects of postmenopausal HRT on IOP in women are not well defined, there is preliminary evidence that premature menopause may be associated with a higher risk for elevated IOP and glaucoma. 37, 38 Harris-Yitzhak et al 39 have recently reported that postmenopausal HRT reduces vascular resistance distal to the ophthalmic artery to levels matching those of premenopausal women. Furthermore, Wickham 40 has lately found that estrogen receptor mRNA exists in a variety of ocular tissues, suggesting that these sites may represent target organs for this hormone. Altinas, 8 Sator, 9 and Sorrentino 10 reported a significant decrease in IOPs in normal postmenopausal women 2 to 3 months following initiation of hormone replacement therapy. Sator also reported a decrease in IOP in a glaucoma patient following HRT. 5 In contrast, Toker 11 reported no change in IOPs following postmenopausal HRT, and Paganini 41 found no influence of the estrogen antagonist tamoxifen on the risk for glaucoma. Our cross-sectional controlled study did not detect any significant differences between HRT and non-HRT users in terms of IOP, C/D ratios, or history of glaucoma.
Several limitations should be considered when interpreting this study's results. The fact that visual fields were not tested in the study patients precludes the diagnosis of glaucoma. However, IOPs, C/D ratios, and history of glaucoma that were recorded consistently in this study generally correlate well with glaucoma. This was a cross-sectional study with no longterm follow-up perspective. The study was powered to detect differences in IOPs of 13% or more between the HRT and non-HRT groups. Smaller differences may not have been detected, despite reaching the study's target sample size. The participation rate was around 70%, which is acceptable. However, a recruitment bias toward patients with visual problems can not be ruled out, since these patients may have been more easily recruited. The prevalence of increased IOP and glaucoma in this study were in accord with previous studies [42] [43] [44] [45] [46] suggesting that such a bias was not present. We used standardized but not validated questionnaires for this study. This could potentially bias the results toward the null (type II error), since random misclassification of variables may occur. Nonetheless, since in cross-sectional studies questionnaires are not filled out repetitively, such validation is difficult. Furthermore, in search of the literature we were unable to find reports of such validated questionnaires. Although menopausal data was consistently obtained from all patients, serum hormonal levels were not measured.
Notwithstanding the above-mentioned limitations, this is one of only few controlled studies to comprehensively assess the effect of postmenopausal HRT and lifetime exogenous and endogenous hormonal exposure on IOP. In comparison to previous studies [42] [43] [44] [45] [46] this study enrolled a relatively older and homogenous cohort of patients in whom the risk for increased IOP was assumed to be higher. This allowed for higher power of analysis and more reliable results to be achieved. Larger scale prospective trials are required to further clarify the effects of postmenopausal HRT as well as lifetime estrogen and progesterone exposure on IOP and glaucoma. Differentiation between the net effects of estrogen and progesterone is indicated in view of their diverse vasoactive and metabolic functions.
CONCLUSION
Postmenopausal hormone replacement therapy does not affect the risk for increased intraocular pressure. Ischemic heart disease may be associated with a higher risk for this disorder. Values are represented as means 6 SD. Numbers in brackets represent percentages. IOP, intraocular pressure; OR, multivariateadjusted odds ratios; CI, confidence interval; HRT, hormone replacement therapy; OC, oral contraceptives. *Not including patients with previous history of glaucoma. None of the comparisons showed statistically significant differences. The multivariate analysis included the same variables as in Table 3 .
